Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
NCT04549363
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
16
Enrollment
INDUSTRY
Sponsor class
Stopped
The study has been terminated for reasons pertaining to feasibility
Conditions
Multiple Myeloma
Interventions
DRUG:
Belantamab mafodotin
Sponsor
GlaxoSmithKline